

RSC Advances



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This Accepted Manuscript will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about Accepted Manuscripts in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

Metal Catalyst Free One-Pot Synthesis of 2-Arylbenzimidazoles From α -Aroylketene Dithioacetals (AKDTAs)**Pandi Dhanalakshmi, Solaimalai Thimmarayaperumal, Shanmugam Sivakumar ****Received (in XXX, XXX) Xth XXXXXXXXX 20XX, Accepted Xth XXXXXXXXX 20XX*


DOI: 10.1039/b000000x

An efficient green synthetic approach has been developed towards the synthesis of 2-aryl substituted benzimidazoles from α -aryloketene dithioacetals (AKDTAs) **1** and *o*-phenylenediamine (OPD) **2**. The reaction has been achieved in water with a catalytic amount of acetic acid. 2-Arylbenzimidazoles have been synthesized in remarkable yields under both thermal and microwave conditions. The metal catalyst free condition makes this transformation very green, practical and attractive.


Introduction

A great number of biologically active molecules contain the benzimidazole scaffold and especially 2-substituted benzimidazole has been found to be biologically more potent.¹⁵ Their application is further extended as poli(ADP-ribose) phosphorilase inhibitors¹ Histamine H4 receptor binders,² antiparasitic,³ cardiovascular,⁴ anticancer,⁵ antimicrobial,⁶ and antihypertensive⁶ agents. In addition, benzimidazoles have been found to have antiulcer activity and ionodilator applications (Fig 1).⁷ The AKDTAs **1** are three carbon synthons, and they are highly functionalized α,β -unsaturated ketones containing both electron withdrawing carbonyl group and electron donating alkylthio substituents well known as polarised or push-pull or donor-acceptor double bond. The alkylthio group is a very good leaving group and it can be easily replaced by nucleophiles. In several reactions, the AKDTAs **1** behave as α,β -unsaturated carbonyl compounds wherein, depending upon the nucleophile / reaction conditions either 1,2- or 1,4- addition takes place. In acidic media nucleophiles prefer 1,2- addition and it has been extensively used for the synthesis of wide variety of heterocyclic compounds.⁸

Several methods have been reported for the synthesis of 2-substituted benzimidazole.⁹⁻¹¹ Generally, the conventional method involves the reaction of aryl aldehyde / carboxylic acid or their derivatives with 1,2-diamines to afford benzimidazole at elevated temperature in the presence of strong acids like polyphosphoric acid,¹² and mineral acid,¹³⁻¹⁵ Several other catalysts like indium triflate,¹⁶ iodine,¹⁷ cetylpyridinium bromide¹⁸ PEG-400¹⁹ (bromodimethyl)sulfonium bromide,²⁰ ammonium acetate,²¹ cobalt(II) chloride hexahydrate,²² ceric ammonium nitrate²³ and enzymatic catalyst Lipozyme²⁴ have been used instead of mineral acids for this cyclocondensation. Recently, substituted benzimidazole has been reported by reacting **2** with aryl aldehydes using 4-OMe-TEMPO as the catalyst under aerobic condition.²⁵ In addition, C-N bond formation *via* a cross coupling reaction, direct C-H activation, using transition metal catalyst have also been reported to construct the benzimidazole

skeleton.²⁶**Fig 1** Structures of representative benzimidazole core motif

The distinctive methods of assembling these valuable heterocycles are highly dependent on using **2** as the precursor. The literature for the other methods to the synthesis of 2-arylbenzimidazoles have been seriously reviewed (Scheme 1).²⁷⁻³²

**Scheme 1** Strategies for the synthesis of 2-arylbenzimidazoles

Water mediated organic synthesis has become one of the most attractive protocol in view of the environment aspects. We now report a conceptually novel, simple and effective metal catalyst free direct cyclocondensation of readily available AKDTAs **1**

with **2** in the presence of acetic acid as a catalyst in water to afford **4** in excellent yields. The development of lab route for the synthesis of benzimidazole **4** under metal catalyst free and eco-friendly condition is worth to consider for it's practical approach on a larger scale operations. Rao *et al* reported trisubstituted pyrrole³³ and 3-aryl coumarin³⁴ by reacting AKDTA with TosMIC and salicylaldehydes respectively. In continuation of exploring the synthetic potential of AKDTAs **1**, we were interested to construct seven membered benzodiazepine derivatives which are pharmacologically and biologically valuable.³⁵⁻³⁷

Table 1 Synthesis of AKDTA **1a-v**³⁴

Entry	Ar	Yield ^a (%)
1	C ₆ H ₅	88
2	2-naphthyl	92
3	1-naphthyl	85
4	4-Cl C ₆ H ₄	92
5	4-CH ₃ C ₆ H ₄	82
6	Ferrocenyl	85
7	Pyrenyl	80
8	3- NO ₂ C ₆ H ₄	80
9	3-OCH ₃ C ₆ H ₄	85
10	2-F C ₆ H ₄	84
11	3-CF ₃ C ₆ H ₄	85
12	4-Br C ₆ H ₄	80
13	4-OCH ₃ C ₆ H ₃	80
14	2,4-Cl ₂ C ₆ H ₃	82
15	3,4-F ₂ C ₆ H ₃	83
16	3,4-Cl ₂ C ₆ H ₃	79
17	3-Br C ₆ H ₄	84
18	2-CF ₃ C ₆ H ₄	84
19	2-F,5-CF ₃ C ₆ H ₃	70
20	4-I C ₆ H ₄	77
21	2-F,4-CF ₃ C ₆ H ₃	72
22	3-CF ₃ ,4-Cl C ₆ H ₃	77

^aisolated yield after recrystallizations

Following the literature³⁴, a variety of AKDTAs **1** has been synthesized (Table 1). Further, heated the mixture of AKDTA **1m** and **2** in the presence of glacial acetic acid (g/v) at 100 °C for 30 min (Scheme 2). The reaction went smoothly and the crude product was purified by recrystallization with ethanol.



Scheme 2 Cyclocondensation between **1m** & **2** in AcOH

The isolated product was well characterized by ¹H and ¹³C NMR spectra. Anticipating the compound to be **3**, the ¹H NMR spectrum displayed a singlet at δ 12.86 for the aromatic NH-proton and one singlet at δ 3.82 for OMe group, a pair of doublets at δ 7.09, 8.09 ppm with mutual coupling a constant *J* = 8.8 Hz for the two CH proton of phenyl group of **1m**. Two multiplets

were appeared at δ 7.14-7.15 & 7.46-7.59 for the CH aromatic protons of **2**. But no peak was noticed for the -SMe group and the olefinic proton at δ 2.48 ppm and δ 6.86 ppm. Thus the NMR data is not matching with compound **3** but it is perfectly matching with **4m** and mass spectrum [m/z 225 (M+1)] also confirms the formation of benzimidazole. Extensive literature studies revealed that this is the first report to the synthesis of 2-arylbenzimidazole **4** from AKDTA **1**. Some of the earlier reports for the synthesis of 2-arylbenzimidazole involve the use of expensive metal catalysts, more reaction time & steps and expensive reagents. The advantages of the present method is, metal catalyst free and less reaction time with excellent yields. The starting materials AKDTA **1**, all of them are solids & stable, high melting points and can be easily preparable with simple reaction techniques. Hence, we report the synthesis of 2-arylbenzimidazole by conceptually novel method of cyclocondensation between AKDTAs **1** and **2** is worth to consider. The cyclocondensation was optimized with **4**, which was observed through several reactions between AKDTA **1** and **2** (Table 2).

Table 2 Optimization of the reaction condition towards the synthesis of **4** from **1& 2**.

Entry	Solvent	Catalyst (mol %)	Tem. (°C)	time (h)	Yield (%)
1	None	None	100	3	Nr ^a
2	None	AcOH (100)	rt	72	60 ^b
3	None	AcOH(100)	100	0.25	75
4	None	AcOH (40)	100	0.5	87
5	None	AcOH (30)	100	0.5	65 ^b
6	None	Formic acid (50)	80	3	- ^c
7	EtOH	None	90	3	Nr ^a
8	EtOH	AcOH (40)	90	3	60 ^b
9	MeCN	AcOH (40)	80	2	75 ^b
10	MeCN	Yb(OTf) ₂ (50)	80	5	65 ^b
11	DMF	Yb(OTf) ₂ (50)	100	5	75 ^b
12	EtOH	p-TsOH (40, MW)	100	0.5	83
13	EtOH	p-TsOH (40, MW)	100	0.02	85 ^e
14	H ₂ O	p-TsOH (MW)	100	0.02	50
15	H ₂ O	H ₂ SO ₄ (1M)	100	0.5	- ^c
16	H ₂ O	HCl (1M)	100	0.5	50 ^b
17	H ₂ O	AcOH (100)	100	1	87
18	H ₂ O	AcOH (40)	rt	120	20 ^b
19	H₂O	AcOH (40)	100	2	95^d

^areaction failed to occur ^bunreacted **1** & **2** recovered


^cComplex reaction mixture ^dIsolated yield.

Once **4m** had been synthesized, several cyclocondensation were tried by variation of reaction conditions (Table 2). The reaction time increased gradually when we reduced the amount of AcOH. Absence of acetic acid did not give the product **4m** (Table 2, entry 1). We examined the mild Lewis acid Ytterbium (III) trifluoromethanesulfonate (Yb(OTf)₃) with two different solvents to afford **4m** in 65 & 75% yields (Table 2, entry 10 & 11). With catalytic amount of p-TsOH in ethanol, the reaction proceeded smoothly in both thermal (30 mins) and MW (2 mins) condition with good yield (Table 2, entry 12-13). The drawback of this condition is, in water / p-TsOH media under microwave condition only 50% of product was observed (Table 2, entry 14). In HCl, the yield was very low and under H₂SO₄, formic acid media did not give the desired product (Table 2, entry 15 -16 & 6). The reaction was performed in ethanol, acetonitrile and water as

solvents in the presence of AcOH (40 mol %) at 100 °C. Among the above solvents, mixture of water-AcOH (40 mol %) gave **4m** in maximum yield (95%, Table 2, entry 19). The optimal reaction conditions were as a result of 2-(4-methoxyphenyl)-1*H*-benzo[d]imidazole **4m** with **2** in the presence of water-AcOH (40 mol %) at 100 °C for 2 h. Overall, the synthesis of 2-arylbenzimidazoles from AKDTA **1** and **2** proceeds only in the presence of acid medium.

In the next step, variation of the aryl groups was studied and synthesized several 2-arylbenzimidazole derivatives **4a-v** using the optimal reaction condition (Table 3). Halogens substituted aryls, polyaryls such as 1 & 2-naphthyl, pyrene and ferrocene substituted benzimidazoles were consecutively investigated and the yields were excellent. Some of the final products **4a**, **4c**, **4f**, **4g**, **4j**, **4l** and **4t** were obtained as pure crystalline product after the simple work-up with saturated sodium bicarbonate solution. Later, we carried out the reaction between **1** and **2** under the microwave irradiation at 100°C for 5 min to furnish **4a-v** in good to excellent yields (78-90 %, Table 3). There is not much differences in yield of the product, when compared with thermal conditions. Thus the shorter reaction time and good to excellent yields encouraged us to repeat all the reactions under microwave irradiation (Table 3).

Table 3: Synthesis of **4a-v** from **1** & **2** in H₂O-AcOH (40 mol %) medium for both thermal and MW conditions.^a




Entry	Ar	Yield	
		Thermal (%)	MW ^c (%)
1	C ₆ H ₅	4a	95 ^b
2	2-naphthyl	4b	92
3	1-naphthyl	4c	93 ^b
4	4-Cl C ₆ H ₄	4d	88
5	4-CH ₃ C ₆ H ₄	4e	87
6	Ferrocenyl	4f	88 ^b
7	Pyrenyl	4g	90
8	3-NO ₂ C ₆ H ₄	4h	89
9	3-OCH ₃ C ₆ H ₄	4i	88
10	2-F C ₆ H ₄	4j	82
11	3-CF ₃ C ₆ H ₄	4k	84
12	4-Br C ₆ H ₄	4l	90 ^b
13	4-OCH ₃ C ₆ H ₄	4m	90
14	2,4-Cl ₂ C ₆ H ₃	4n	85
15	3,4-F ₂ C ₆ H ₃	4o	84
16	3,4-Cl ₂ C ₆ H ₃	4p	83
17	3-Br C ₆ H ₄	4q	89
18	2-CF ₃ C ₆ H ₄	4r	83
19	2-F,5-CF ₃ C ₆ H ₃	4s	80
20	4-I C ₆ H ₄	4t	90 ^b
21	2-F,4-CF ₃ C ₆ H ₃	4u	87
22	3-CF ₃ , 4-Cl C ₆ H ₃	4v	87

^a All reactions carried out with (1mmol), **2** (1mmol), AcOH (40 mol %), water at 100 °C (i) thermal 2 h. (ii) MW, 5 min. ^byields after recrystallization, ^cisolated yield.

There are number of mechanism envisioned for the formation of 2-arylbenzimidazole **4** from *o*-phenylenediamine **2** with aldehyde or acid or acid chloride etc. Based on the results, we propose a plausible mechanism for the one-pot synthesis of **4** by the cyclocondensation of AKDTA **1** and **2** (Scheme 3). When the mixture of AKDTA **1** and **2** with catalytic glacial acetic acid heated at 100 °C, initially **1** get protonated followed by instantaneous nucleophilic addition of amine group of **2** at C-1 position to give imine (**II**). This imine formation makes the C-1 position more electron deficient and attract the further nucleophilic addition by another amine group of **2** to afford five membered heterocycle 2-(2,2-bis(methylthio)vinyl)-2-phenyl-2,3-dihydro-1*H*-benzo[d]imidazole (**III**). In order to achieve the aromaticity, elimination of ethynyl(methyl)sulfane **5** by cleavage of C-C bond of ketene group and MeSH **6** has occurred to afford **4** in excellent yields. Elimination of **5** & **6** is the driving force for the formation of **4**.

55



Scheme 5 Plausible mechanism for the two component cyclocondensation

70 Conclusions

In summary, we have demonstrated the synthesis of substituted aryl benzimidazoles from AKDTAs **1a-v** and readily available **2** under mild and greener medium in excellent yields for both thermal and MW conditions. It is noteworthy that this methodology is very simple, less time, metal catalyst free, involving eco-friendly solvent and milder reaction conditions. The economical and environmental advantages of their protocol adds practical value for the industrial applications.

Experimental Section

80 General methods

The melting points reported in the work are uncorrected. Unless stated otherwise, solvents and chemicals were obtained from commercial sources and used without further purification. The ¹H and ¹³CNMR spectra of the new compounds were measured at 300,400MHz in DMSO-d₆ and CDCl₃. Chemical shifts are reported as δ values (ppm) relative to tetramethylsilane (δ 0.0) as

internal standard. Mass spectra were obtained using electrospray ionization (ESI) mass spectrometer and recorded in positive and negative mode. Infrared spectra were recorded on an FT-IR spectrometer with the major peaks listed. HRMS (ESI-TOF) analysis were recorded on mass spectrometer. Petroleum ether employed in column chromatographic purification refers to the fraction which boils at 40–60 °C. Microwave reactions have been carried out in a Biotage Microwave Synthesizer

10 General procedure for the preparation of 3,3-bis(methylthio)-1-arylprop-2-en-1-one (1a–v):

To a stirred suspension of freshly prepared sodium *tert*-butoxide (6.0g, 0.0625mol) in dry benzene (5ml) at 0°C a solution of arylethanone (3g, 0.0250mol) and carbon disulfide (2.87g, 0.0375mol) in dry benzene (5ml) was added through a pressure equalizer funnel and the mixture was vigorously stirred at 0°C for 90min. Appearance of a reddish solid in the reaction medium indicated the formation of disodium 3-oxo-3-(3-phenyl)-1-propene-1,1-dithiolate. A solution of methyl iodide (4.26g, 0.030mol) in dry benzene (5ml) was carefully added to this suspension, drop-wise during 10 min at 0°C and the reaction mixture was allowed to stir at 0°C for 90min. After completion of the reaction (TLC; hexanes: EtOAc = 7:3), the mixture was transferred into a 100ml beaker containing 50g of crushed ice and the contents of the beaker were stirred well. A light yellow coloured solid formed was filtered and washed with water (10ml × 3). The crude solid was re-crystallized from EtOH to furnish 3.10g of 1,1-di(methylsulfanyl)-3-(aryl)-1-propen-3-one in 80–92% yield as light yellow colored crystals.

3,3-bis(methylthio)-1-phenylprop-2-en-1-one³⁴ (1a).

Pale yellow solid; yield 88%, mp. 94–96 °C; ¹H NMR (400 MHz, DMSO-d₆) δ_H: 2.48 (s, 3H), 2.64 (s, 3H), 6.86 (s, 1H), 7.49 (d, J = 7.6Hz, 2H), 7.56 (d, J = 7.6Hz, 1H), 7.94 (d, J = 6.8Hz, 1H), 7.94 (m, 2H). ¹³C NMR (75 MHz, CDCl₃) δ_C: 14.9, 17.2, 109.3, 127.6, 128.3, 131.6, 139.2, 166.3, 185.5. LC-MS calcd. m/z 224, found 225[(M+1)]⁺.

40 3,3-bis(methylthio)-1-(naphthalen-2-yl)prop-2-en-1-one³⁴ (1b).

Yellow solid; yield 92%, mp. 96–98 °C; ¹H NMR (400 MHz, DMSO-d₆) δ_H: 2.49 (s, 3H), 2.71 (s, 3H), 7.05 (s, 1H), 7.57–7.64 (m, 2H), 7.95 – 8.02 (m, 3H), 8.10 (d, J = 7.2Hz, 1H), 8.62 (s, 1H). ¹³C NMR (75 MHz, CDCl₃) δ_C: 15.1, 17.4, 109.6, 124.3, 126.5, 127.6, 127.7, 128.4, 129.3, 132.6, 134.9, 136.6, 166.3, 185.5. LC-MS calcd. m/z 274, found 275[(M+1)]⁺.

3,3-bis(methylthio)-1-(naphthalen-1-yl)prop-2-en-1-one³⁴ (1c).

Yellow solid; yield 85%, mp. 79–82 °C; ¹H NMR (300 MHz, CDCl₃) δ_H: 2.46 (s, 3H), 2.57 (s, 3H), 6.56 (s, 1H), 7.45–7.54 (m, 2H), 7.70 (d, J = 8Hz, 1H), 7.92 (d, J = 12Hz, 1H). ¹³C NMR (75 MHz, CDCl₃) δ_C: 14.8, 17.1, 113.5, 124.5, 125.8, 126.0, 126.8, 128.1, 130.1, 130.7, 133.6, 138.9, 165.9, 189.3. LC-MS calcd. m/z 274, found 275[(M+1)]⁺.

55 1-(4-chlorophenyl)-3,3-bis(methylthio)prop-2-en-1-one³⁴ (1d).

Yellow solid; yield 92%, mp. 104–106 °C; ¹H NMR (400 MHz, DMSO-d₆) δ_H: 2.47 (s, 3H), 2.65 (s, 3H), 6.84 (s, 1H), 7.54 (d, J = 8.4 Hz, 2H), 7.97 (d, J = 8.4 Hz, 2H). ¹³C NMR (75 MHz, CDCl₃) δ_C: 14.9, 17.3, 108.9, 128.6, 129.0, 137.7, 183.8. * LC-MS calcd. m/z 258, found 259[(M+1)]⁺. [*Two carbon signals have merged together].

= 8.4 Hz, 2H), 7.97 (d, J = 8.4 Hz, 2H). ¹³C NMR (75 MHz, CDCl₃) δ_C: 14.9, 17.3, 108.9, 128.6, 129.0, 137.7, 183.8. * LC-MS calcd. m/z 258, found 259[(M+1)]⁺. [*Two carbon signals have merged together].

3,3-bis(methylthio)-1-p-tolylprop-2-en-1-one³⁴ (1e).

65 Yellow solid; yield 82%, mp. 98–100 °C; ¹H NMR (400 MHz, DMSO-d₆) δ_H: 2.49 (s, 3H), 2.63 (s, 3H), 2.78 (s, 1H), 6.84 (s, 1H), 7.23 (d, J = 8.8 Hz, 2H), 7.64 (d, J = 8.8 Hz, 2H). ¹³C NMR (75 MHz, CDCl₃) δ_C: 15.0, 17.3, 55.4, 21.5, 109.6, 127.8, 129.1, 136.7, 142.3, 165.5, 185.4. LC-MS calcd. m/z 238, found 70 239[(M+1)]⁺.

3,3-bis(methylthio)-1-ferrocenyl-2-propen-1-one³⁴ (1f).

75 Yellow solid; yield: 85%, mp. 112–114 °C; ¹H NMR (400 MHz, DMSO-d₆) δ_H: 2.42 (s, 3H), 2.60 (s, 3H), 4.16 (s, 4H), 4.50 (s, 1H), 4.83 (s, 2H), 6.41 (s, 1H). ¹³C NMR (75 MHz, CDCl₃) δ_C: 14.9, 17.4, 69.0, 69.8, 71.6, 81.6, 111.3, 160.9, 189.3. LC-MS calcd. m/z, found [(M+1)]⁺.

3,3-bis(methylthio)-1-pyrenyl-2-propen-1-one³³ (1g).

80 Yellow solid; yield: 80% yield, mp. 150–152 °C; ¹H NMR (400 MHz, DMSO-d₆) δ_H: 2.56 (s, 3H), 2.61 (s, 3H), 6.82 (s, 1H), 7.35 (s, 1H), 8.13 (t, J = 8 Hz, 1H), 8.22 – 8.29 (m, 3H), 8.33 – 8.38 (m, 4H), 8.63 (d, J = 9.2Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ_C: 15.0, 17.3, 114.2, 124.2, 124.8, 124.9, 125.5, 126.2, 127.1, 128.3, 128.5, 128.7, 128.8, 130.6, 132.7, 135.7, 189.6 *. LC-MS calcd. m/z 348, found 349[(M+1)]⁺. [*Two carbon signals have merged together].

3,3-bis(methylthio)-1-(3-nitrophenyl)prop-2-en-1-one³⁸ (1h).

90 Yellow solid; yield: 80%, M.pt. 110–112 °C; ¹H NMR (400 MHz, CDCl₃) δ_H: 2.57 (s, 3H), 2.62 (s, 3H), 6.74 (s, 1H), 7.64 (t, J = 8Hz, 1H), 8.26 (d, J = 8Hz, 1H), 8.35 (d, J = 8Hz, 1H), 8.71 (s, 1H). ¹³C NMR (75 MHz, CDCl₃) δ_C: 14.5, 16.8, 107.3, 121.7, 125.3, 128.9, 132.9, 140.1, 147.6, 169.6, 181.9. LC-MS calcd. 95 m/z 269, found 270[(M+1)]⁺.

1-(3-methoxyphenyl)-3,3-bis(methylthio)prop-2-en-1-one³⁸ (1i).

Yellow solid; yield 84%, mp. 88–90 °C; ¹H NMR (400 MHz, DMSO-d₆) δ_H: 2.49 (s, 3H), 2.65 (s, 3H), 3.80 (s, 3H), 6.83 (s, 1H), 7.13 (d, J = 8 Hz, 1H), 7.41 (t, J = 8 Hz, 2H), 7.54 (d, J = 8Hz, 1H). ¹³C NMR (75 MHz, CDCl₃) δ_C: 14.9, 17.3, 55.3, 109.4, 112.4, 117.9, 119.9, 129.3, 140.7, 159.7, 166.5, 185.2. LC-MS calcd. m/z 254, found 255[(M+1)]⁺.

105 1-(2-fluorophenyl)-3,3-bis(methylthio)prop-2-en-1-one³⁸ (1j).

Yellow solid; yield: 84%, mp. 70–72 °C. ¹H NMR (400 MHz, DMSO-d₆) δ_H: 2.50 (s, 3H), 2.58 (s, 3H), 6.66 (s, 1H), 7.28 – 7.33 (m, 2H), 7.55–7.61 (m, 1H), 7.75 (t, J = 8Hz, 1H). ¹³C NMR (75 MHz, CDCl₃) δ_C: 15.1, 17.3, 113.2, 113.3, 116.0, 116.3, 124.4, 127.5, 127.7, 131.2, 132.9, 133.1, 158.8, 162.1, 167.0, 182.3. LC-MS calcd. m/z 242, found 243[(M+1)]⁺.

115 3,3-bis(methylthio)-1-(3-(trifluoromethyl)phenyl)prop-2-en-1-one³⁸ (1k).

Yellow solid; yield: 85%, mp. 88–90 °C; ¹H NMR (400 MHz,

DMSO-d₆) δ_{H} : 2.49 (s, 3H), 2.68 (s, 3H), 6.90 (s, 1H), 7.74 (t, J = 8 Hz, 1H), 7.92 (d, J = 8 Hz, 1H), 8.18 (s, 1H), 8.28 (d, J = 7.6 Hz, 1H). ¹³C NMR (75 MHz, CDCl₃) δ_{C} : 15.0, 17.3, 108.4, 124.4, 128.0, 128.9, 130.7, 131.1, 139.9, 168.8, 183.7. LC-MS calcd. m/z 292, found 293[(M+1)]⁺.

1-(4-bromophenyl)-3,3-bis(methylthio)prop-2-en-1-one³⁹ (1l). Yellow solid; yield: 80%, mp. 100-104 °C; ¹H NMR (400 MHz, DMSO-d₆) δ_{H} : 2.50 (s, 3H), 2.66 (s, 3H), 6.84 (s, 1H), 7.69 (d, J = 8.8 Hz, 1H), 7.91 (d, J = 8.4 Hz, 1H). ¹³C NMR (75 MHz, CDCl₃) δ_{C} : 14.4, 16.8, 108.3, 125.8, 129.0, 131.1, 137.5, 167.1, 183.2 *. LC-MS calcd. m/z 303, found 304[(M+1)]⁺. [*Two carbon signals have merged together].

15 **1-(4-methoxyphenyl)-3,3-bis(methylthio)prop-2-en-1-one³⁹ (1m).**

Yellow solid; yield: 80%, mp. 100-102 °C; ¹H NMR (400 MHz, DMSO-d₆) δ_{H} : 2.45 (s, 3H), 2.63 (s, 3H), 3.82 (s, 1H), 6.84 (s, 1H), 7.00 (d, J = 8.8 Hz, 2H), 7.94 (d, J = 8.8 Hz, 2H). ¹³C NMR (75 MHz, CDCl₃) δ_{C} : 15.1, 17.3, 55.4, 109.8, 113.7, 129.4, 132.2, 162.6, 164.6, 184.6 *. LC-MS calcd. m/z 254, found 255[(M+1)]⁺. [* Two carbon signals have merged together].

16 **1-(2,4-dichlorophenyl)-3,3-bis(methylthio)prop-2-en-1-one⁴⁰ (1n).**

Yellow solid; yield: 82%, mp. 108-110 °C; ¹H NMR (400 MHz, DMSO-d₆) δ_{H} : 2.49 (s, 3H), 2.54 (s, 3H), 6.44 (s, 1H), 7.50 (d, J = 9.2 Hz, 1H), 7.58 (d, J = 8 Hz, 1H), 7.68 (s, 1H). ¹³C NMR (75 MHz, CDCl₃) δ_{C} : 15.0, 17.2, 112.5, 127.2, 129.9, 130.8, 131.7, 136.2, 138.8, 167.7, 184.9. LC-MS calcd. m/z 293, found 294[(M+1)]⁺.

17 **1-(3,4-difluorophenyl)-3,3-bis(methylthio)prop-2-en-1-one (1o).**

Yellow solid; yield: 83%, mp. 137 °C; ¹H NMR (400 MHz, DMSO-d₆) δ_{H} : 2.49 (s, 3H), 2.68 (s, 3H), 6.81 (s, 1H), 7.43- 7.48 (m, 1H), 7.65 (d, J = 6.8 Hz, 1H). ¹³C NMR (75 MHz, CDCl₃) δ_{C} : 15.0, 17.3, 106.7, 108.1, 110.3, 110.7, 142.5, 161.1, 161.3, 164.4, 164.6, 169.5, 182.3. LC-MS calcd. m/z 260 found 261[(M+1)]⁺. HRMS (ESI-TOF) calcd for C₁₁H₁₀F₂OS₂Na [M + Na]⁺ 283.0039 found 283.0034.

18 **1-(3,4-dichlorophenyl)-3,3-bis(methylthio)prop-2-en-1-one (1p).**

Yellow solid; yield: 79%, mp. 118-120 °C; ¹H NMR (400 MHz, DMSO-d₆) δ_{H} : 2.48 (s, 3H), 2.67 (s, 3H), 6.83 (s, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.93 (d J = 8.4 Hz, 1H), 8.14 (s, 1H). ¹³C NMR (75 MHz, CDCl₃) δ_{C} : 15.1, 17.4, 108.1, 126.7, 129.6, 130.4, 132.8, 135.9, 138.9, 168.9, 182.6. LC-MS calcd. m/z 293, found 294[(M+1)]⁺. HRMS (ESI-TOF) calcd for C₁₁H₁₀Cl₂OS₂Na [M + Na]⁺ 314.9448 found 314.9440.

19 **1-(3-bromophenyl)-3,3-bis(methylthio)prop-2-en-1-one (1q).**

Yellow solid; yield: 84%, mp. 78-80 °C; ¹H NMR (400 MHz, DMSO-d₆) δ_{H} : 2.48 (s, 3H), 2.67 (s, 3H), 6.83 (s, 1H), 7.46 (t, J = 8 Hz, 1H), 7.75 (d, J = 8 Hz, 1H), 7.96 (d, J = 7.6 Hz, 1H), 8.07 (s, 1H). ¹³C NMR (75 MHz, CDCl₃) δ_{C} : 15.1, 17.5, 108.7, 122.7, 126.3, 130.1, 130.8, 134.5, 141.3, 168.3, 183.9. LC-MS calcd.

m/z 303, found 304[(M+1)]⁺. HRMS (ESI-TOF) calcd for C₁₁H₁₁BrOS₂Na [M + Na]⁺ 324.9332 found 324.9326.

3,3-bis(methylthio)-1-(2-(trifluoromethyl)phenyl)prop-2-en-1-one (1r)

Pale yellow solid; yield: 84%, mp. 108-110 °C; ¹H NMR (300 MHz, CDCl₃) δ_{H} : 2.46 (s, 3H), 2.54 (s, 3H), 6.26 (s, 1H), 7.27- 7.61 (m, 3H), 7.69 (d, J = 8Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ_{C} : 16.9, 19.1, 78.6, 79.0, 79.4, 114.1, 128.2, 128.3, 129.1, 130.1, 131.3, 133.7, 143.4, 169.8, 189.5. LC-MS calcd. m/z 292, found 293[(M+1)]⁺. HRMS (ESI-TOF) calcd for C₁₂H₁₁F₃OS₂Na [M + Na]⁺ 315.0101 found 315.0093

1-(2-fluoro-5-(trifluoromethyl)phenyl)-3,3-bis(methylthio)prop-2-en-1-one (1s).

Yellow solid; yield: 70%, mp. 88-90 °C; ¹H NMR (400 MHz, DMSO-d₆) δ_{H} : 2.51 (s, 3H), 2.58 (s, 3H), 6.66 (s, 1H), 7.57 (t, J = 9.2 Hz, 1H), 7.95 - 8.02 (m, 1H). ¹³C NMR (75 MHz, CDCl₃) δ_{C} : 15.3, 17.4, 112.4, 117.1, 119.4, 124.8, 126.3, 127.5, 128.2, 129.2, 129.9, 160.8, 163.3, 169.6, 180.4. LC-MS calcd. m/z 310, found 311[(M+1)]⁺. HRMS (ESI-TOF) calcd for C₁₂H₁₀F₄OS₂Na [M + Na]⁺ 333.0007 found 333.0003

1-(4-iodophenyl)-3,3-bis(methylthio)prop-2-en-1-one (1t).

Yellow solid; yield: 77%, mp. 88-90 °C; ¹H NMR (400 MHz, DMSO-d₆) δ_{H} : 2.49 (s, 3H), 2.64 (s, 3H), 6.82 (s, 1H), 7.73 (d, J = 8 Hz, 1H), 7.86 (d, J = 8 Hz, 1H). ¹³C NMR (75 MHz, CDCl₃) δ_{C} : 15.1, 17.4, 99.1, 108.7, 128.0, 129.3, 137.7, 138.7, 167.7, 184.68*. LC-MS calcd. m/z 350, found 351[(M+1)]⁺. HRMS (ESI-TOF) calcd for C₁₁H₁₁IOS₂Na [M + Na]⁺ 372.9194 found 372.9190. [*Two carbon signals have merged together].

90

1-(2-fluoro-4-(trifluoromethyl)phenyl)-3,3-bis(methylthio)prop-2-en-1-one (1u).

Yellow solid; yield: 72%, mp. 84-86 °C; ¹H NMR (400 MHz, DMSO-d₆) δ_{H} : 2.51 (s, 3H), 2.57 (s, 3H), 6.63 (s, 1H), 7.67 (d, J = 8 Hz, 1H), 7.79 (d, J = 10.4 Hz, 1H), 7.92 (t, J = 8 Hz, 1H). ¹³C NMR (75 MHz, CDCl₃) δ_{C} : 15.2, 17.4, 112.4, 113.8, 113.9, 114.0, 121.3, 121.4, 121.5, 124.3, 130.7, 132.2, 134.3, 134.7, 158.6, 161.2, 169.6, 180.7. LC-MS calcd. m/z 310, found 311[(M+1)]⁺. HRMS (ESI-TOF) calcd for C₁₂H₁₀F₄OS₂Na [M + Na]⁺ 333.0007 found 333.0001.

1-(4-chloro-3-(trifluoromethyl)phenyl)-3,3-bis(methylthio)prop-2-en-1-one (1v).

Yellow solid; yield: 77%, mp. 126-128 °C; ¹H NMR (400 MHz, DMSO-d₆) δ_{H} : 2.49 (s, 3H), 2.68 (s, 3H), 6.88 (s, 1H), 7.85 (d, J = 8 Hz, 1H), 8.25 (s, 1H), 8.29 (d, J = 8 Hz, 1H). ¹³C NMR (75 MHz, CDCl₃) δ_{C} : 15.2, 17.5, 107.9, 121.2, 123.9, 126.8, 126.9, 128.5, 128.8, 131.7, 135.0, 135.6, 137.9, 169.8, 182.7. LC-MS calcd. m/z 326, found 327[(M+1)]⁺. HRMS (ESI-TOF) calcd for C₁₂H₁₀ClF₃OS₂Na [M + Na]⁺ 348.9711 found 348.9708.

2. General method for the synthesis of (E)-aryl 1H-benzo[d]-benzimidazole (4a-v).

Method 1 (Conventional heating method). To the mixture of AKDTA 1 (1mmol), *o*-phenylenediamine 2 (1mmol), acetic acid (40 mol %) in water (6ml) was added and heated at 100 °C for 2h.

The reaction mixture was treated with sodium bicarbonate and extracted with ethyl acetate. The combined ethylacetate extracts were washed with water, dried and concentrated under rotary vacuum evaporation. The crude residue was recrystallized to obtain pure solid product **4a-v** (80-95% yields).

Method II (Microwave irradiation method). A 10 ml glass vial sealed by septum, containing a mixture of AKDTA **1** (1mmol) *o*-phenylenediamine **2** (1mmol), and acetic acid (40 mol %) in water (6ml) was placed in microwave synthesizer. The vial was then subjected to microwave irradiation programmed at 120W, 100 °C with 1bar pressure. After completion of the reaction (5min), the vial was cooled to room temperature and extracted with ethyl acetate and the crude was purified by recrystallization in ethanol to yield pure **4a-v** (78-90%).

2-phenyl-1*H*-benzo[*d*]imidazole⁴¹ (**4a**)

Off white crystalline solid; yield: 95% (thermal), 90% (MW), mp. 296 °C. UV λ_{max} (MeOH) = 241 nm (log ε = 2.39), 202 nm (log ε = 2.61), ¹H NMR (400MHz, DMSO-d₆) δ_H: 7.15-7.22 (m, 2H), 7.46-7.75 (m, 4H), 7.65 (d, *J* = 7.6Hz, 1H), 8.16 (d, *J* = 6.8Hz, 2H), 12.86 (s, 1H). ¹³C NMR (75MHz, DMSO-d₆) δ_C: 111.3, 118.9, 121.7, 122.5, 126.4, 128.9, 129.8, 130.2, 135.0, 143.8, 151.2. LC-MS calcd. m/z: 194, found 195 [(M+1)]⁺.

25

2-(naphthalene-2-yl)1*H*-benzo[*d*]imidazole⁴² (**4b**)

Off white solid; yield: 92% (thermal), 90% (MW), mp. 214-215 °C. UV λ_{max} (MeOH) = 316 nm (log ε = 2.75), 281 nm (log ε = 2.65), 241 nm (log ε = 2.88). ¹H NMR (400MHz, DMSO-d₆) δ_H: 7.19-7.23 (m, 2H), 7.54-7.69 (m, 4H), 7.97-8.08 (m, 3H), 8.30 (d, *J* = 8.4Hz, 1H), 8.72 (s, 1H), 13.03 (s, 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ_C: 129.0, 131.1, 131.6, 131.8, 132.7, 133.3, 133.3, 137.9, 138.6, 156.7. * LC-MS calcd.m/z: 244 found 245[(M+1)]⁺. [*Two carbon signals have merged together].

35

2-(naphthalene-1-yl)1*H*-benzo[*d*]imidazole⁴¹ (**4c**)

Off white solid; yield: 93% (thermal), 87% (MW), mp 270-272 °C; UV λ_{max} (MeOH) = 306nm (log ε = 2.58), 226 nm (log ε = 2.88), ¹H NMR (400MHz, DMSO-d₆) δ_H: 7.22 - 7.26 (m, 2H), 7.58-7.68 (m, 5H), 7.80-8.04 (m, 2H), 8.08 (d, *J* = 8.4Hz, 1H), 9.10 (d, *J* = 7.6Hz, 1H), 12.92 (s, 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ_C: 122.4, 125.5, 126.6, 126.8, 127.3, 128.3, 128.7, 130.4, 131.1, 134.0, 151.8. LC-MS calcd.m/z: 244, found 245 [(M+1)]⁺.

45

2-(4-chlorophenyl)1*H*-benzo[*d*]imidazole⁴¹ (**4d**)

Off white solid; yield: 88% (thermal), 82% (MW), mp. 290-292 °C; UV (MeOH) λ_{max} = 307 nm (log ε = 2.77), 245 nm (log ε = 2.45). ¹H NMR (400MHz, DMSO-d₆) δ_H: 7.20 (s, 2H), 7.52 (d, *J* = 6.8Hz, 1H), 7.61(d, *J* = 8.8Hz, 2H), 7.66 (s, 1H), 8.17 (d, *J* = 8.4Hz, 2H), 12.94 (s, 1H). ¹³C NMR (75MHz, DMSO-d₆) δ_C: 122.5, 128.3, 129.1, 129.3, 135.3, 150.7*. LC-MS calcd.m/z: 228, found 229 [(M+1)]⁺ [*Two carbon signals have merged together].

55

2-p-tolyl-1*H*-benzo[*d*]imidazole⁴¹ (**4e**)

Off white solid; yield: 87% (thermal), 82% (MW), mp. 275-277 °C; UV λ_{max} (MeOH) = 304nm (log ε = 2.77), 243 nm (log ε =

2.53). ¹H NMR (400MHz, DMSO-d₆) δ_H: 7.13 - 7.20 (m, 2H), 7.34 (d, *J* = 8Hz, 2H), 7.49 (d, *J* = 6.4Hz, 1H), 7.62 (d, *J* = 7.6Hz, 1H), 8.05 (d, *J* = 8Hz, 2H), 12.76 (s, 1H). ¹³C NMR (75MHz, DMSO-d₆) δ_C: 22.0, 112.8, 127.4, 128.4, 130.3, 140.4, 152.5*. LC-MS calcd.m/z: 208, found 209 [(M+1)]⁺. [*Two carbon signals have merged together].

65

2-(ferrocenyl-2-yl)1*H*-benzo[*d*]imidazole⁴³ (**4f**)

Off white solid; yield: 88% (thermal), 83% (MW), mp. 300 °C; UV λ_{max} (MeOH) = 304 nm (log ε = 2.70), 206 nm (log ε = 2.93). ¹H NMR (400MHz, DMSO-d₆) δ_H: 4.08 (s, 4H), 4.45 (s, 2H), 5.02 (s, 2H), 7.08-7.15 (m, 2H), 7.42 (d, *J* = .8Hz, 1H), 7.52 (d, *J* = 7.6Hz, 1H), 12.30 (s, 1H). ¹³C NMR (100MHz, DMSO-d₆) δ_C: 60.7, 69.8, 70.2, 74.8, 110.9, 118.4, 121.8, 153.4. LC-MS calcd.m/z: 303, found 304 [(M+1)]⁺.

2-(pyren-2-yl)1*H*-benzo[*d*]imidazole (**4g**)

Off white solid; yield: 90% (thermal), 87% (MW), mp. 300 °C; UV λ_{max} (MeOH) = 351 nm (log ε = 3.51), 278 nm (log ε = 2.69), 241 nm (log ε = 2.87). IR (KBr): 3423, 3043, 1743, 1649, 1421, 1278, 1018, 842, 746 cm⁻¹. ¹H NMR (400MHz, DMSO-d₆) δ_H: 7.26-7.28 (m, 2H), 7.71-7.74 (m, 2H), 8.20 (t, *J* = 7.6Hz, 1H), 8.27-8.37 (m, 3H), 8.45 (d, *J* = 8Hz, 1H), 8.56 (d, *J* = 8Hz, 1H), 9.51(d, *J* = 9.2Hz, 1H), 13.13 (s, 1H). ¹³C NMR (100MHz, DMSO-d₆) δ_C: 122.6, 124.2, 124.8, 125.1, 125.3, 126.0, 126.1, 126.4, 127.1, 127.8, 128.9, 129.1, 130.8, 131.4, 132.0. LC-MS calcd.m/z: 318, found 319 [(M+1)]⁺. HRMS (ESI-TOF) calcd for C₂₃H₁₆N₂Na [M + Na]⁺ 343.1211 found 343.1208.

2-(3-nitrophenyl)1*H*-benzo[*d*]imidazole⁴⁴ (**4h**)

Off white solid; yield: 89% (thermal), 82% (MW), mp. 208-210 °C; UV λ_{max} (MeOH) = 306 nm (log ε = 2.64), 245 nm (log ε = 2.52). ¹H NMR (400MHz, DMSO-d₆) δ_H: 7.20-7.28 (m, 2H), 7.57 (d, *J* = 7.6Hz, 1H), 7.71 (d, *J* = 8Hz, 1H), 7.85 (t, *J* = 8Hz, 1H), 8.32 (d, *J* = 8.4Hz, 1H), 8.60 (d, *J* = 8Hz, 1H), 9.00 (s, 1H), 13.25 (s, 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ_C: 111.8, 119.5, 121.3, 122.3, 123.4, 124.1, 130.4, 132.2, 132.7, 135.4, 143.9, 148.6, 149.4. LC-MS calcd.m/z: 239, found 240 [(M+1)]⁺.

2-(3-methoxyphenyl)1*H*-benzo[*d*]imidazole⁴⁵ (**4i**)

Off white solid; yield: 88% (thermal), 83% (MW), mp. 210-212 °C; UV λ_{max} (MeOH) = 306 nm (log ε = 2.74), 210 nm (log ε = 2.91). ¹H NMR (400MHz, DMSO-d₆) δ_H: 3.85 (s, 3H), 7.03-7.06 (m, 1H), 7.19 (s, 2H), 7.44 (t, *J* = 8.4Hz, 1H), 7.53 (s, 1H), 7.64 (s, 1H), 7.73-7.75 (m, 2H), 12.84 (s, 1H). ¹³C NMR (100MHz, DMSO-d₆) δ_C: 55.8, 111.9, 116.3, 119.2, 122.6, 130.6, 131.9, 151.6, 160.1*. LC-MS calcd.m/z: 224, found 225 [(M+1)]⁺. [*Two carbon signals have merged together].

2-(2-fluorophenyl)1*H*-benzo[*d*]imidazole (**4j**)

Off white solid; yield: 82% (thermal), 79% (MW), mp. 205-206 °C; UV λ_{max} (MeOH) = 303 nm (log ε = 2.87), 206 nm (log ε = 3.02). IR (KBr): 3425, 2854, 1739, 1423, 1018, 748 cm⁻¹. ¹H NMR (400MHz, DMSO-d₆) δ_H: 7.12-7.25 (m, 2H), 7.36-7.45 (m, 2H), 7.52-7.58 (m, 2H), 7.68 (d, *J* = 7.2Hz, 1H), 8.23 (t, *J* = 8Hz, 1H), 12.53 (s, 1H). ¹³C NMR (75MHz, DMSO-d₆) δ_C: 115.9, 116.3, 117.3, 117.5, 125.1, 125.1, 130.1, 131.5, 131.6, 131.6, 146.9, 158.6, 161.9. LC-MS calcd.m/z: 212, found 213

$[(M+1)]^+$ HRMS (ESI-TOF) calcd for $C_{13}H_9FN_2Na$ $[M + Na]^+$ 235.0647 found 235.0641.

2-(3-(trifluoromethyl)phenyl)1*H*-benzo[*d*]imidazole⁴⁶ (4k)

Off white solid; yield: 84% (thermal), 80% (MW), mp. 206-208 °C; UV λ_{max} (MeOH) = 306 nm ($\log \epsilon = 2.77$), 206 nm ($\log \epsilon = 2.90$). 1H NMR (400MHz, DMSO-d₆) δ_H : 7.19-7.26 (m, 2H), 7.56 (d, $J = 7.6Hz$, 1H), 7.69 (d, $J = 7.2Hz$, 1H) 7.77-7.85 (m, 2H), 8.46 (d, $J = 7.6Hz$, 1H), 8.51 (s, 1H), 13.12 (s, 1H). ^{13}C NMR (75MHz, DMSO-d₆) δ_C : 111.4, 119.3, 122.2, 123.1, 123.6 126.0, 129.4, 130.0, 130.7, 131.1, 131.4, 135.2, 150.3. LC-MS calcd.m/z: 262, found 263 $[(M+1)]^+$.

2-(4-bromophenyl)1*H*-benzo[*d*]imidazole⁴⁴ (4l)

Off white solid; yield: 90% (thermal), 85% (MW), mp. 296-298 °C; UV λ_{max} (MeOH) 308 nm ($\log \epsilon = 2.72$), 246 nm ($\log \epsilon = 2.46$). 1H NMR (400MHz, DMSO-d₆) δ_H : 7.16-7.24 (m, 2H), 7.52 (d, $J = 7.2Hz$, 1H), 7.65 (d, $J = 7.6Hz$, 1H), 7.75 (d, $J = 8.4Hz$ 2H), 8.10 (d, $J = 8.4Hz$, 2H), 12.94 (s, 1H). ^{13}C NMR (75 MHz, DMSO-d₆) δ_C : 122.6, 123.8, 128.6, 129.7, 132.0, 150.8. * LC-MS calcd.m/z: 212, found 213 $[(M+1)]^+$. [*Two carbon signals have merged together].

2-(4-methoxyphenyl)1*H*-benzo[*d*]imidazole⁴⁴ (4m)

Off white solid; yield: 90% (thermal), 88% (MW), mp. 225-226 °C; UV λ_{max} (MeOH) = 307nm ($\log \epsilon = 2.82$), 248 nm ($\log \epsilon = 2.52$), 1H NMR (400MHz, DMSO-d₆) δ_H : 3.82 (s, 3H), 7.09 (d, $J = 8.8Hz$, 2H), 7.14-7.15 (m, 2H), 7.46-7.59 (m, 2H), 8.09 (d, $J = 8.8Hz$, 2H), 12.68 (s, 1H). ^{13}C NMR (75MHz, DMSO-d₆) δ_C : 14.6, 122.1, 123.2, 128.4, 151.9, 161.0 *. LC-MS calcd.m/z: 224, found 225 $[(M+1)]^+$. [*Two carbon signals have merged together].

2-(2,4-dichlorophenyl)1*H*-benzo[*d*]imidazole⁴⁷ (4n)

Off white solid; yield: 85% (thermal), 81% (MW), mp. 216-218 °C; UV λ_{max} (MeOH) = 296 nm ($\log \epsilon = 2.56$), 207 nm ($\log \epsilon = 2.95$). 1H NMR (400MHz, DMSO-d₆) δ_H : 7.23-7.24 (m, 2H), 7.59-7.62 (m, 3H), 7.82 (s, 1H), 7.93 (d, $J = 8.4Hz$, 1H), 12.72 (s, 1H). ^{13}C NMR (75MHz, DMSO-d₆) δ_C : 127.4, 132.2, 133.5, 134.3, 137.6, 137.8, 140.5, 153.2. * LC-MS calcd.m/z: 262, found 263 $[(M+1)]^+$. [*Two carbon signals have merged together].

2-(3,4-difluorophenyl)1*H*-benzo[*d*]imidazole (4o)

Off white solid; yield: 84% (thermal), 78% (MW), mp. 230 °C; UV λ_{max} (MeOH) = 306 nm ($\log \epsilon = 2.69$), 242 nm ($\log \epsilon = 2.39$). IR (KBr): 3445, 3300, 1620, 1400, 1200, 1080, 760 cm⁻¹. 1H NMR (400MHz, DMSO-d₆) δ_H : 7.19-7.28(m, 2H), 7.36-7.40 (m, 1H), 7.55 (d, $J = 8Hz$, 1H), 7.68 (d, $J = 7.6Hz$, 1H), 7.84 (d, $J = 7.4Hz$, 2H), 13.05 (s, 1H). ^{13}C NMR (75MHz, DMSO-d₆) δ_C : 104.9, 105.2, 105.6, 109.6, 109.9, 111.9, 119.6, 122.5, 123.5, 133.8, 133.9, 134.1, 135.3 143.9, 149.3, 161.4, 161.6, 164.7, 164.88. LC-MS calcd.m/z: 230, found 231 $[(M+1)]^+$. HRMS (ESI-TOF) calcd for $C_{13}H_8F_2N_2Na$ $[M + Na]^+$ 253.0553 found 253.0548.

2-(3,4-dichlorophenyl)1*H*-benzo[*d*]imidazole (4p)

Off white crystalline solid; yield: 83% (thermal), 80% (MW), mp. 235 °C; UV λ_{max} (MeOH) = 294 nm ($\log \epsilon = 2.60$), 205 nm ($\log \epsilon$

= 2.90). IR (KBr): 3439, 3380, 1590, 1590, 1312, 1020, 800 cm⁻¹. 1H NMR (400MHz, DMSO-d₆) δ_H : 7.23 (t, $J = 8.4Hz$, 2H), 7.54 (d, $J = 7.2Hz$, 1H), 7.67 (d, $J = 7.6Hz$, 1H), 7.83 (d, $J = 8.4Hz$, 1H), 8.14 (d, $J = 8.8Hz$, 1H), 8.38 (s, 1H), 13.05 (s, 1H). ^{13}C NMR (75MHz, DMSO-d₆) δ_C : 115.8, 122.7, 127.8, 129.2, 130.2, 132.9, 133.5, 135.5, 139.3, 148.5 *. LC-MS calcd.m/z: 263, found 264 $[(M+1)]^+$. HRMS (ESI-TOF) calcd for $C_{13}H_8Cl_2N_2Na$ $[M + Na]^+$ 284.9962 found 284.9955. [*Two carbon signals have merged together].

2-(3-bromophenyl)1*H*-benzo[*d*]imidazole⁴⁴ (4q)

Off white solid; yield: 89% (thermal), 84% (MW), mp. 262-264 °C; UV λ_{max} (MeOH) = 306 nm ($\log \epsilon = 2.79$), 207 nm ($\log \epsilon = 2.95$). 1H NMR (400MHz, DMSO-d₆) δ_H : 7.19-7.27 (m, 2H), 7.50 - 7.56 (m, 2H), 7.67 - 7.70 (m, 2H), 8.18 (d, $J = 8Hz$, 1H), 8.37 (s, 1H), 13.00 (s, 1H). ^{13}C NMR (75MHz, DMSO-d₆) δ_C : 155.0, 137.4, 137.2, 135.4, 130.2, 127.5.* LC-MS calcd.m/z: 273, found 274 $[(M+1)]^+$. [*Two carbon signals have merged together].

2-(2-(trifluoromethyl)phenyl)1*H*-benzo[*d*]imidazole⁴⁸ (4r)

White crystalline solid; yield: 83% (thermal), 79% (MW), mp. 274-276 °C; UV λ_{max} (MeOH) = 282 nm ($\log \epsilon = 2.47$), 206 nm ($\log \epsilon = 2.92$). 1H NMR (400MHz, DMSO-d₆) δ_H : 7.18 - 7.26 (m, 2H), 7.52 (d, $J = 8Hz$, 1H), 7.67 (d, $J = 7.6Hz$, 1H), 7.74-7.85 (m, 3H), 7.93 (d, $J = 7.6Hz$, 1H), 12.72 (s, 1H). ^{13}C NMR (75MHz, DMSO-d₆) δ_C : 127.1, 131.1, 133.5, 134.5, 136.5, 137.1, 154.4.* LC-MS calcd. m/z: 262, found 263 $[(M+1)]^+$. [*Two carbon signals have merged together].

2-(2-fluoro-5-(trifluoromethyl)phenyl)1*H*-benzo[*d*]imidazole (4s)

Off white crystalline solid; yield: 80% (thermal), 78% (MW), mp. 215°C; UV λ_{max} (MeOH) = 307 nm ($\log \epsilon = 2.73$), 206 nm ($\log \epsilon = 2.89$). IR (KBr): 3441, 3053, 2924, 1789, 1404, 1332, 1159, 752 cm⁻¹. 1H NMR (400MHz, DMSO-d₆) δ_H : 7.24 - 7.30 (m, 2H), 7.61 (d, $J = 7.6Hz$, 1H), 7.75 (dd, $J = 8.4Hz$, $J = 7.2Hz$, 2H), 7.94 (d, $J = 10.8Hz$, 1H), 8.46 (t, $J = 8Hz$, 1H), 12.77 (s, 1H). ^{13}C NMR (75MHz, DMSO-d₆) δ_C : 105.2, 109.6, 109.9, 111.9, 119.6, 122.5, 123.5, 133.9, 134.1, 135.3, 143.9, 149.3, 161.6, 164.7. LC-MS calcd.m/z: 280, found 281 $[(M+1)]^+$. HRMS (ESI-TOF) calcd for $C_{14}H_8F_4N_2Na$ $[M + Na]^+$ 303.0521 found 303.0516.

2-(4-iodophenyl)1*H*-benzo[*d*]imidazole⁴⁹ (4t)

Off white crystalline solid; yield: 90% (thermal), 86% (MW), mp. 290-292 °C; UV λ_{max} (MeOH) = 310 nm ($\log \epsilon = 2.82$), 252 nm ($\log \epsilon = 2.53$). 1H NMR (400MHz, DMSO-d₆) δ_H : 7.16-7.19 (m, 1H), 7.56-7.58 (m, 1H), 7.92 (dd, $J = 8Hz$, 8.4Hz, 2H). ^{13}C NMR (75MHz, DMSO-d₆) δ_C : 96.2, 122.4, 128.6, 130.2, 137.9, 150.9*. LC-MS calcd.m/z: 320, found 321 $[(M+1)]^+$. [*Two carbon signals have merged together].

2-(2-fluoro-4-(trifluoromethyl)phenyl)1*H*-benzo[*d*]imidazole (4u).

Off white solid; yield: 87% (thermal), 82% (MW), mp. 230 °C; UV λ_{max} (MeOH) = 308 nm ($\log \epsilon = 2.75$), 206 nm ($\log \epsilon = 2.85$). IR (KBr): 3441, 3086, 1770, 1444, 1332, 1130, 740⁻¹. 1H NMR (400MHz, DMSO-d₆) δ_H : 7.24-7.30 (m, 2H), 7.61 (d, $J = 7.6Hz$, 1H), 7.75 (dd, $J = 8.4Hz$, $J = 7.2Hz$, 2H), 7.94 (d, $J = 10.8Hz$, 1H), 12.77 (s, 1H). ^{13}C NMR (75MHz, DMSO-d₆) δ_C : 105.2, 109.6, 109.9, 111.9, 119.6, 122.5, 123.5, 133.9, 134.1, 135.3, 143.9, 149.3, 161.6, 164.7. LC-MS calcd.m/z: 280, found 281 $[(M+1)]^+$. HRMS (ESI-TOF) calcd for $C_{14}H_8F_4N_2Na$ $[M + Na]^+$ 303.0521 found 303.0516.

1H), 8.46 (t, J = 8Hz, 1H), 12.77 (s, 1H). ^{13}C NMR (75MHz, DMSO-d₆) δ _C: 112.4, 113.8, 114.1, 119.4, 121.7, 122.4, 123.5, 131.4, 135.4, 143.2, 157.7, 161.1. LC-MS calcd.m/z: 280, found 281 [(M+1)].⁺ HRMS (ESI-TOF) calcd for C₁₄H₈F₄N₂Na [M + Na]⁺ 303.0521 found 303.0516.

2-(4-chloro-3-(trifluoromethyl)phenyl)1*H*-benzo[d]imidazole (4v)

Off white solid; yield: 87% (thermal), 83% (MW), mp. 200 °C;
¹⁰ UV λ_{max} (MeOH) = 309 nm ($\log \epsilon$ = 2.78), 246 nm ($\log \epsilon$ = 2.50). IR (KBr): 3444, 3053, 1618, 1438, 1317, 1180, 743 cm⁻¹. ^1H NMR (400MHz, DMSO-d₆) δ _H: 7.20 - 7.28 (m, 2H), 7.56 (d, J = 7.6Hz, 1H), 7.69 (d, J = 8Hz, 1H), 7.92 (d, J = 8.4Hz, 1H), 8.44 (d, J = 8.4Hz, 1H), 8.61(s, 1H). ^{13}C NMR (75MHz, DMSO-d₆) δ _C: 129.3, 130.6, 133.1, 133.5, 134.4, 135.7, 136.6, 137.6, 154.2. * LC-MS calcd.m/z: 296, found 297 [(M+1)].⁺ HRMS (ESI-TOF) calcd for C₁₄H₈ClF₃N₂Na [M + Na]⁺ 319.0226 found 319.0220. [*Two carbon signals have merged together].

Acknowledgments

SS thanks UGC and DST-MRP for the financial assistance. PD thanks UGC for meritorious fellowship. We thank DST-IRHPA for fundings towards higher resolution NMR spectrometer. We thank Prof. H. Surya Prakash Rao, Department of Chemistry, Pondicherry University, Puducherry for generous help in recording spectra and helpful discussions

Notes and references

Department of Organic Chemistry, School of Chemistry, Madurai Kamaraj University, Madurai 625021, India.
e-mail: shivazzen@mku.ac.in

† Electronic Supplementary Information (ESI) available: Copies of representative spectra See DOI: 10.1039/b000000x/

- 1 A. W. White, N. J. Curtin, B. W. Eastman, B. T. Golding, Z. Hostomsky, S. Kyle, K. A. Maegley, D. J. Skalitzki, S. E. Webber, X.-H. Yu, and R. J. Griffin, *Bioorg. Med. Chem. Lett.*, 2004, **14**, 2433-2437.
- 2 A. Lee-Dutra, K. L. Arienti, D. J. Buzard, M. D. Hack, H. Khatuya, P. J. Desai, S. Nguyen, R. L. Thurmond, L. Karlsson, J. P. Edwards and J. G. Breitenbucher, *Bioorg. Med. Chem. Lett.* 2006, **16**, 6043-6048.
- 3 R. C. Rivera, O. Munoz, *J. Med. Microbiol.*, 1992, **37**, 221-224.
- 4 T. Güngör, A. Fouquet, J.-M. Teulon, D. Provost, M. Cazes and A. Cloarec, *J. Med. Chem.*, 1992, **35**, 4455-4563.
- 5 W. A. Denny, G. W. Newcastle, and B. C. Baguley, *J. Med. Chem.*, 1990, **33**, 814-819.
- 6 E. Seyhan, N. Sultan, A. Nilgun, and N. Noyanalpan, *Arzneimittel-Forschung* 1997, **47**, 410-412.
- 7 P. C. Santhosh, S. N. Pandeya and K.P. Ashish, *IJRAP*, 2011, **6**, 1726-1737.
- 8 (a) R. K. Dieter, *Tetrahedron*, 1986, **42**, 3029-3096. (b) H. Junjappa, H. Ila, and C. V. Ashokan, *Tetrahedron*, 1990, **46**, 5423-5506.
- 9 A. R. Katritzky and A. J. Boulton, *Advances in Heterocyclic Chemistry*; Vol 27; Academic: New York, 1980, **27**, 241.
- 10 S. P. Siva, M. Ritu, C. J. Subhash, *Current Organic Chemistry*, 2012, **16**, 1905-1919.
- 11 C. Anshul, K. Gurpreet and K. S. Anil, *Int. J. Pharm. Phytopharacol. Res.*, 2012, **3**, 148-159.
- 12 P. N. Preston A. Weissberger and E. C. Taylor, *Chemistry of Heterocyclic Compounds*; Part-1, Wiley: New York, 1981, **40**, 6-60.

- 13 A. R. Katritzky and C. W. Rees, *Comprehensive Heterocyclic Chemistry*; Pergamon: Oxford, 1984, **5**, 457-474.
- 14 R. R. Nagawade and B. D. Shinde, *Chin. Chem lett.*, 2006, **17**, 453-456.
- 15 H. Xiangming, M. Huiqiang and W. Yulu, *W. Arkivoc*. **2007**, 150-154.
- 16 R. Trivedi, S. K. De and R. A. Gibbs, *J Mol Cat A chem.*, 2006, **245**, 8-11.
- 17 P. Gogoi and D. Konwar, *Tetrahedron Lett.*, 2006, **47**, 79-82.
- 18 M. Chakrabarty, S. Karmakar, R. Mukherjee, S. Arima Y. Harigaya, *Monatsh Chem.*, 2009, **140**, 375-380.
- 19 C. Mukhopadhyay and P. K. Tapaswi, *Tetrahedron Lett.*, 2008, **49**, 6237-6240.
- 20 B. Das, H. Holla and Y. Srinivas, *Tetrahedron Lett.* 2007, **48**, 61-64.
- 21 H. Sharghi, O. Asemani and R. Khalifeh, *Synth Commun.* 2008, **38**, 1128-1136.
- 22 A. T. Khan and T. Parvin, *Cheminform*. 2009, **40**, 2339-2346.
- 23 M. Kidwai, A. Jahan. *J. Chem. Sci.*, 2010, **122**, 607-612.
- 24 G. Renard, D. A. Lerner. *New. J. Chem.*, **2007**, *31*, 1417-1420.
- 25 Y. X. Chen, L. -F. Qian, W. Zhang and B. Han, *Angew. Chem. Int. Ed.*, 2008, **47**, 9330-9333.
- 26 For recent reviews and references on benzimidazole synthesis (a) L. C. R Carvalho, E. Fernandes and M. M. B. Marques, *Chem-Eur. J.* 2011, **17**, 12544 -12555. (b) C. T. Brain and J. T Steer, *J. Org.Chem.* 2003, **68**, 6814- 6816. (c) K. Hirano, A. T. Biju and F. Glorius, *J. Org.Chem.* 2009, **74**, 9570- 9572. (d) N. Zheng, K. W. Anderson, X. Huang, H. N. Nguyen and S. L. Buchwald, *Angew.Chem.Int. Ed.*, 2007, **46**, 7509- 7512. (e) G. Brasche and S. L. Buchwald, *Angew. Chem. Int. Ed.*, 2008, **47**, 1932- 1934.(f) R. K. Kumar and T. Punniyamurthy, *RSC Adv.* 2012, **2**, 4616-4619. (g) P. Saha, M. A. Ali, P. Ghosh and T. Punniyamurthy, *Org. Biomol.Chem.* 2010, **8**, 5692-5699. (h) H. Jin, X. Xu, J. Gao, J. Zhong and Y. Wang, *Adv. Synth. Catal.* 2010, **352**, 347-350. (i) S. Fu, H. Jiang, Y. Deng, W. Zeng, *Adv. Synth. Catal.* 2011, **353**, 2795-2804.
- 27 Y. Kim, M. R. Kumar, N. Park, Y. Heo and S. Lee, *J. Org. Chem.* 2011, **76**, 9577- 9583.
- 28 L. Keurulainen, O. Salin, A. Siiskonen, J. M. Kern, P. Kiuru, M. Maass, J. Y. Kauhaluoma and P. Vuorela, *J. Med. Chem.*, 2010, **53**, 7664-7674.
- 29 Z. H. Zhang, L. Yin and Y. M. Wang, *Catal. Commun.* 2007, **8**, 1126 - 1131.
- 30 S. Y. Lin, Y. Isome, E. Stewart, J. F. Liu, D. Yohanees and L. Yu, *Tetrahedron Lett.*, 2006, **47**, 2883-2886.
- 31 X. Diao, Y. Wang, Y. Jiang and D. Ma, *J. Org. Chem.*, 2009, **74**, 7974-7977.
- 32 H. Nishioka, Y. Ohmori, Y. Iba, E. Tsuda and T. Harayama, *Heterocycles*, 2004, **64**, 193-198.
- 33 H. S. P. Rao and S. Sivakumar, *Beilstein. J. Org. Chem.* 2007, **3**, 31.
- 34 H. S. P. Rao and S. Sivakumar, *J. Org. Chem.* 2006, **71**, 8715-8723.
- 35 (a) L. O. Randall and B. Kappel, *In Benzodiazepines*; S. Garattini, E. Mussini, L. O. Randall, Raven Press: New York, 1973, 27. (b) H. Schutze, *Benzodiazepines*; Springer: Heidelberg, Germany, 1982. (c) J. K. Landquist, *In Comprehensive Heterocyclic Chemistry*; A. R. Katritzky, C. W. Rees, Pergamon: Oxford, U.K. 1984; Vol. 1, p 166. (d) G. A. Archer, and L. H. Sternbach, *Chem. Rev.* 1968, **68**, 747-784. (e) R. Langnickel, R. Bluth and T. Ott, *Pharmazie* 1986, **41**, 689-694. (f) A. L. Parola, H. I. Yamamura, and H. E. Laird, *Life Sci.* 1993, **52**, 1329-1342.
- 36 S. Michelini, G. B. Cassano, F. Frare, G. Perugi, *Pharmacopsychiatry* 1996, **29**, 127-134.
- 37 (a) J. Knabe, H. P. Buech and S. Bender, *Arch. Pharm.* 1995, 328, 59-66. (b) R.N. Brodgen, R.C. Heel, T. M. Speight and G. S. Avery, *Drugs* 1980, **20**, 161-178.
- 38 A. Alija, M. Martin, S. Hartmut, K. Heinz, D. Sara, F. Mary, B. John and G. Andrew, *PCT Int. Appl.*, 2003053967, 2003
- 39 R. K. Verma, G. K. Verma, G. Shukla and M. S. Singh, *RSC adv.*, 2012, **2**, 2413-2421.
- 40 E. Heiner, P. Stefan and H. Silke, *PCT Int. Appl.*, 2008145681, 2008
- 41 R. G. Xing, Y. N. Li, Q. Liu, Q. Y. Meng, J. Li, X. X. Shen, Z. Liu, B. Zhou, X. Yao and Z. L. Liu, *Eur. J. Org. Chem.*, 2006, 6627-6632

- 42 M. A. Chari, D. Shobha, T. Sasaki, *Tetrahedron Lett.*, 2011, **52**, 5575-5580.
- 43 A. Benito, M. Manez, J. payfi, J. Soto, M. Tendero and E. Sinn, *J. Organomet. Chem.*, 1995, **503**, 259-263.
- 44 D. Saha, A. Saha and B. C. Ranu, *Green Chem.*, 2009, **11**, 733-737.
- 45 B. M. Savall and J. Fontimayor, *Tetrahedron Lett.*, 2008, **49**, 6667-6669.
- 46 G. M. Coppola, *Synth. Commun.*, 2008, **38**, 3500-3507
- 47 M. A. Charia, D .Shobha, E. R. Kenawy, S. S. A. Deyab, B. V. S. Reddy, A. Vinu, *Tetrahedron Lett.*, 2010, **51**, 5195-5199.
- 48 M. Shen, and T. G. Driver, *Org. Lett.*, 2008, **10**, 3367-3370
- 49 S. K. Xiang, W. Tan, D. X. Zhang, X. L. Tian, C. Feng, B. Q. Wang, K. Q. Zhao, P. Hu, H. Yang, *Org. Biomol. Chem.*, 2013, DOI: 10.1039/C3OB41479E.